DE602005022435D1 - Chromenderivate mit anti-tubulin- und gefässabzielender wirkung - Google Patents

Chromenderivate mit anti-tubulin- und gefässabzielender wirkung

Info

Publication number
DE602005022435D1
DE602005022435D1 DE602005022435T DE602005022435T DE602005022435D1 DE 602005022435 D1 DE602005022435 D1 DE 602005022435D1 DE 602005022435 T DE602005022435 T DE 602005022435T DE 602005022435 T DE602005022435 T DE 602005022435T DE 602005022435 D1 DE602005022435 D1 DE 602005022435D1
Authority
DE
Germany
Prior art keywords
well
vascular
tubulin
objectives
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005022435T
Other languages
English (en)
Inventor
Kevin G Pinney
Phyllis Arthasary
Anupama Shirali
Klaus Edvardsen
David J Chaplin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxi Gene Inc
Baylor University
Original Assignee
Oxi Gene Inc
Baylor University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/837,841 external-priority patent/US20050245489A1/en
Application filed by Oxi Gene Inc, Baylor University filed Critical Oxi Gene Inc
Publication of DE602005022435D1 publication Critical patent/DE602005022435D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE602005022435T 2004-05-03 2005-05-03 Chromenderivate mit anti-tubulin- und gefässabzielender wirkung Active DE602005022435D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/837,841 US20050245489A1 (en) 2004-05-03 2004-05-03 Chromene-containing compounds with anti-tubulin and vascular targeting activity
US10/851,445 US7456214B2 (en) 2004-05-03 2004-05-21 Chromene-containing compounds with anti-tubulin and vascular targeting activity
PCT/US2005/015276 WO2005113532A1 (en) 2004-05-03 2005-05-03 Chromene-derivatives with anti-tubulin and vascular targeting activity

Publications (1)

Publication Number Publication Date
DE602005022435D1 true DE602005022435D1 (de) 2010-09-02

Family

ID=35045098

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005022435T Active DE602005022435D1 (de) 2004-05-03 2005-05-03 Chromenderivate mit anti-tubulin- und gefässabzielender wirkung

Country Status (5)

Country Link
US (1) US7456214B2 (de)
EP (1) EP1751128B1 (de)
AT (1) ATE474830T1 (de)
DE (1) DE602005022435D1 (de)
WO (1) WO2005113532A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46558E1 (en) 2005-04-28 2017-09-26 Paloma Pharmaceuticals, Inc. Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
NZ570014A (en) 2006-02-03 2011-04-29 Bionomics Ltd Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
WO2007101247A2 (en) * 2006-02-28 2007-09-07 Paloma Pharmaceuticals, Inc. Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
GB0610804D0 (en) * 2006-05-31 2006-07-12 Portela & Ca Sa New crystal forms
TW200927740A (en) * 2007-11-13 2009-07-01 Bial Portela & Ca Sa Process
WO2009072915A1 (en) * 2007-12-05 2009-06-11 Bial - Portela & Ca., S.A. New salts and crystal forms
WO2009103076A1 (en) * 2008-02-15 2009-08-20 Oxigene, Inc. Methods and compositions for enhancing the efficacy of rtk inhibitors
JP5679582B2 (ja) * 2008-03-25 2015-03-04 パロマ ファーマシューティカルズ，インク． 線維性障害を処置する方法
US9006284B2 (en) 2009-08-27 2015-04-14 Bionomics Limited Combination therapy for treating proliferative diseases
NZ598490A (en) 2009-08-27 2014-01-31 Bionomics Ltd Treatment of macular degeneration
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4656187A (en) 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
IT1212882B (it) 1983-07-29 1989-11-30 Della Valle Francesco Derivati basici della cumarina
JPH07103164B2 (ja) * 1987-02-27 1995-11-08 三菱化学株式会社 光重合性組成物
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US6277879B1 (en) 1994-08-03 2001-08-21 Sarawak Medichem Pharmaceuticals, Inc. Calanolide analogues and methods of their use
US5532382A (en) 1995-03-13 1996-07-02 Eli Lilly And Company Benzothiophenes substituted at the 3-carbonyl
US6545027B1 (en) 1995-06-07 2003-04-08 Eli Lilly And Company Methods of modulating NF-kB transcription factor
CA2214070C (en) 1996-08-29 2006-03-14 Eli Lilly And Company Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
CA2215647A1 (en) 1996-10-24 1998-04-24 Eli Lilly And Company Naphthyl compounds, compositions, and methods
US5886025A (en) 1997-03-06 1999-03-23 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
ATE264304T1 (de) 1997-10-02 2004-04-15 Daiichi Seiyaku Co Dihydronaphthalinderivate und verfahren zur herstellung derselben
US6943194B1 (en) 1998-01-09 2005-09-13 Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University Synthesis of phenstatin and prodrugs thereof
US6162930A (en) 1998-03-06 2000-12-19 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US6291456B1 (en) 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6331562B1 (en) 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
DE19937772A1 (de) 1999-08-10 2001-02-15 Bayer Ag Substituierte Heterocyclyl-2GH-chromene
AU777725B2 (en) 1999-09-17 2004-10-28 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
AU2001243527B9 (en) 2000-03-10 2007-01-18 Baylor University Tubulin binding ligands and corresponding prodrug constructs
BR0109838A (pt) 2000-04-07 2003-01-21 Pfizer Prod Inc Metabólitos de agonista/antagonista de estrogênio
WO2001079180A2 (en) 2000-04-17 2001-10-25 Warner-Lambert Company 5-substituted tetralones as inhibitors of ras farnesyl transferase
CA2407672A1 (en) 2000-04-27 2001-11-01 Matthew P. Grealish Hydroxyphenstatin and the prodrugs thereof
WO2002060887A2 (en) 2001-02-01 2002-08-08 Thomas Jefferson University Synthesis of 4h-chromene derivatives
AUPR283801A0 (en) 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
US20030176494A1 (en) 2001-11-16 2003-09-18 Ze-Qi Xu Novel coumarin and chromene compounds and methods of preparation and use thereof for treating or preventing viral infections
EP1513515A2 (de) 2002-05-16 2005-03-16 Cytovia, Inc. Substitutierte 4h-chromene, 2h-chromene, chromane und analoga als aktivatoren von caspasen und induktoren von apoptose und ihre verwendung
US20060122387A1 (en) 2002-06-13 2006-06-08 Cti Europe S.R.L. Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells

Also Published As

Publication number Publication date
EP1751128B1 (de) 2010-07-21
US7456214B2 (en) 2008-11-25
ATE474830T1 (de) 2010-08-15
US20050245490A1 (en) 2005-11-03
WO2005113532A1 (en) 2005-12-01
EP1751128A1 (de) 2007-02-14

Similar Documents

Publication Publication Date Title
DE602005022435D1 (de) Chromenderivate mit anti-tubulin- und gefässabzielender wirkung
WO2006138427A3 (en) Combretastatin analogs with tubulin binding activity
DE602005025803D1 (de) Stereoisomerisch angereicherte 3-aminocarbonyl-bicyclohepten-pyrimidindiamin-verbindungen und ihre verwendungen
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
NO20033651D0 (no) Cancerbehandling
WO2007008200A8 (en) Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
BRPI0717266A2 (pt) Derivados de oxindol
UA96565C2 (ru) Пиридильные ингибиторы хеджхоговской передачи сигнала
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
SE531352C8 (sv) Spiroalkanderivat och användning av dessa föreningar för behandling av artrit, cancer, kardiovaskulära sjukdomar, hudsjukdomar och inflammatoriska och allergiska tillstånd
CL2009000133A1 (es) Compuestos derivados de ftalazinona, inhibidores de la actividad parp; composicion farmaceutica; uso en el tratamiento de enfermedades vasculares, shock septico, lesion isquemica, neurotoxicidad, shock hemorragico, como auxiliar en la terapia del cancer de mama, de ovario, de pancreas, entre otras.
AR027355A1 (es) Acidos tiazolidincarboxilicos
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
NO20050640L (no) Rutenium anticancer komplekser
WO2006043083A3 (en) Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy
MXPA05006688A (es) Conjugados de polimero con una variante de cianovirina.
WO2008002460A3 (en) Orally available light-independent antineoplastic compounds
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
DE60228544D1 (de) Triptolid-prodrugs zur krebstherapie
WO2003090680A3 (en) Novel phenyl derivatives as inducers of apoptosis
ATE426409T1 (de) Antitumor-kombinationen mit vegf-trap und 5fu oder einem seiner derivate
WO2007086943A3 (en) Wortmannin conjugates and uses thereof
WO2007051119A8 (en) Methods and compositions of parp inhibitors as potentiators in cancer therapy
EA200971103A1 (ru) Иммуноцитокины для лечения рака в сочетании с химиотерапевтическими агентами
WO2008035208A3 (en) The use of polymethoxyflavones for the non apoptotic inhibition of cancer cell growth